Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OncoResponse

OncoResponse?uq=oeHSfu7P
2015 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$29.5M LATEST DEAL AMOUNT
12 INVESTORS
Description

Developer of therapeutic antibodies designed to provide care against immuno-oncology targets. The company's therapeutic antibodies are made from human memory B-cell repertoire for the treatment of cancer, enabling patients to achieve curative and durable responses.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 909 Fannin Street
  • Suite 2100
  • Houston, TX 77024
  • United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoResponse’s full profile, request a free trial.

OncoResponse Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 23-Mar-2017 $29.5M 000.00 000.00 Completed Startup
1. Joint Venture 06-Oct-2015 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

OncoResponse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.00
To view this company’s complete Cap Table, request access »

OncoResponse Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 07-Nov-2017 000000000000000000 Biotechnology 00000000 000000
To view this company’s complete investment and acquisition history, request access »

OncoResponse Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Baxalta Ventures Corporate Venture Capital Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
GreatPoint Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

OncoResponse Executive Team (4)

Name Title Board
Seat
Contact
Info
Clifford Stocks Co-Founder, Chief Executive Officer & Board Member
Russ Hawkinson Chief Financial Officer
Anil Singhal Ph.D Chief Scientific Officer
Kristine Swiderek Ph.D Chief Scientific Officer

OncoResponse Board Members (7)

Name Representing Role Since Contact
Info
Alan Ginsberg OncoResponse Board Member 000 0000
Andrew Perlman GreatPoint Ventures Board Member 000 0000
Clifford Stocks OncoResponse Co-Founder, Chief Executive Officer & Board Member 000 0000
Geeta Vemuri Ph.D Baxalta Ventures Board Member 000 0000
Roberto De Ponti Helsinn Healthcare Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »